Evidence map›Paper›PMID 28143522›Full record

Trial reportTrials2017

ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.

David A Drew, Samantha M Chin, Katherine K Gilpin, Melanie Parziale, Emily Pond, Madeline M Schuck, Kathleen Stewart, Meaghan Flagg, Crystal A Rawlings, Vadim Backman and 18 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Trials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02394769 (ASPIRED), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02394769 naactive not recruitingnot on this map

ASPIRED: ASPirin Intervention for the REDuction of Colorectal Cancer Risk

TypeinterventionalSponsorMassachusetts General HospitalRan2015 to 2029Enrolled180ConditionsColorectal CancerArmsAspirin, Placebo for Aspirin
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 40 citations in OpenAlex.

  1. Effect of Low-dose and Standard-dose Aspirin on PGECancer prevention research (Philadelphia, Pa.) · 2020
    Trial
  2. Colorectal Cancer Chemoprevention: A Dream Coming True?International journal of molecular sciences · 2023
    Review
  3. Colorectal Cancer Risk in Patients with Hemorrhoids: A 10-Year Population-Based Retrospective Cohort Study.International journal of environmental research and public health · 2021
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2019
    Article
  14. Review
  15. Review
  16. NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.Journal of the National Cancer Institute · 2018
    Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 8 institutions in 1 country.

David A DrewClinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Samantha M ChinClinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Katherine K GilpinClinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Melanie ParzialeClinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Emily PondClinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Madeline M SchuckClinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Kathleen StewartDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Meaghan FlaggThe Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Crystal A RawlingsThe Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Vadim BackmanMcCormick School of Engineering, Northwestern University, Evanston, IL, USA.
Peter J CarolanDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Daniel C ChungDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Francis P ColizzoDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Matthew FreedmanBroad Institute, Cambridge, MA, USA.
Manish GalaClinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
John J GarberDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Curtis HuttenhowerDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Dmitriy KedrinDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Hamed KhaliliClinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Douglas S KwonThe Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Sanford D MarkowitzCase Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, OH, USA.
Ginger L MilneEicosanoid Core Laboratory, Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN, USA.
Norman S NishiokaDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
James M RichterDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Hemant K RoySection of Gastroenterology, Boston Medical Center, Boston, MA, USA.
Kyle StallerClinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Molin WangDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Andrew T ChanClinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. achan@mgh.harvard.edu.
Harvard University · USMassachusetts General Hospital · USRagon Institute of MGH, MIT and Harvard · USBroad Institute · USBoston Medical Center · USMcCormick (United States) · USUniversity School · USVanderbilt University · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1993 to 2026
$153.9M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and TreatmentR35CA197442 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARKOWITZ, SANFORD D. · 2017 to 2023
$6.6M
Inflammation and Colorectal NeoplasiaR01CA137178 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2009 to 2019
$6.5M
NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA137178NCI NIH HHS R35 CA197442NIDDK NIH HHS P30 DK043351
6 · The paper itself

Abstract

backgroundAlthough aspirin is recommended for the prevention of colorectal cancer, the specific individuals for whom the benefits outweigh the risks are not clearly defined. Moreover, the precise mechanisms by which aspirin reduces the risk of cancer are unclear. We recently launched the ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED) trial to address these uncertainties. METHODS/

designASPIRED is a prospective, double-blind, multidose, placebo-controlled, biomarker clinical trial of aspirin use in individuals previously diagnosed with colorectal adenoma. Individuals (n = 180) will be randomized in a 1:1:1 ratio to low-dose (81 mg/day) or standard-dose (325 mg/day) aspirin or placebo. At two study visits, participants will provide lifestyle, dietary and biometric data in addition to urine, saliva and blood specimens. Stool, grossly normal colorectal mucosal biopsies and cytology brushings will be collected during a flexible sigmoidoscopy without bowel preparation. The study will examine the effect of aspirin on urinary prostaglandin metabolites (PGE-M; primary endpoint), plasma inflammatory markers (macrophage inhibitory cytokine-1 (MIC-1)), colonic expression of transcription factor binding (transcription factor 7-like 2 (TCF7L2)), colonocyte gene expression, including hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD) and those that encode Wnt signaling proteins, colonic cellular nanocytology and oral and gut microbial composition and function. DISCUSSION: Aspirin may prevent colorectal cancer through multiple, interrelated mechanisms. The ASPIRED trial will scrutinize these pathways and investigate putative mechanistically based risk-stratification biomarkers.

trial registrationThis protocol is registered with the U.S. National Institutes of Health trial registry, ClinicalTrials.gov, under the identifier NCT02394769 . Registered on 16 March 2015.

Indexed as

AdenomaAdolescentAdultAgedAged, 80 and overAnticarcinogenic AgentsAspirinBiomarkers, TumorBostonCarcinomaClinical ProtocolsColorectal NeoplasmsCytokinesDisease ProgressionDouble-Blind MethodFemale7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acidAnticarcinogenic AgentsAspirinBiomarkers, TumorCytokinesInflammation MediatorsProstaglandinsAspirinBiomarkerChemopreventionColorectal cancer

Identifiers

PMID28143522
PMCPMC5286828
OpenAlexW2584843727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.